GLP-1 receptor drugs and their relationship with alcohol use disorder: a systematic review
Updated
Abstract
In three randomized controlled trials involving 48 to 151 participants, semaglutide and dulaglutide were associated with a reduction in alcohol use.
- Semaglutide was linked to a decrease in overall alcohol consumption.
- Dulaglutide showed a reduction in alcohol intake among current drinkers.
- Exenatide did not significantly impact the number of heavy drinking days.
- The findings suggest potential benefits of GLP-1 receptor agonists for alcohol use disorder.
- Further large randomized controlled trials are necessary to confirm these effects.
Simplified